PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer's disease (AD)-related demographic, cognitive, genetic and neuroimaging markers. We examined 771 participants with normal cognition, mild cognitive impairment or dementia from BioFINDER-2 (n = 400) and ADNI (n = 371). All had tau-PET ([¹⁸F]RO948 in BioFINDER-2, [¹⁸F]flortaucipir in ADNI) and CSF p-tau181 biomarkers available. Plasma p-tau181 and plasma/CSF p-tau217 were available in BioFINDER-2 only. Concordance between PET, CSF and plasma tau biomarkers ranged between 66 and 95%. Across the whole group, ridge regression models showed that increased CSF and plasma p-tau181 and p-tau217 levels were independently of tau PET associated with higher age, and APOEɛ4-carriership and Aβ-positivity, while increased tau-PET signal in the temporal cortex was associated with worse cognitive performance and reduced cortical thickness. We conclude that biofluid and neuroimaging markers of tau pathology convey partly independent information, with CSF and plasma p-tau181 and p-tau217 levels being more tightly linked with early markers of AD (especially Aβ-pathology), while tau-PET shows the strongest associations with cognitive and neurodegenerative markers of disease progression.

中文翻译：

---

与 CSF 和血浆 p-tau 生物标志物相比，Tau PET 与不同的阿尔茨海默病相关特征相关

tau 病理学的 PET、CSF 和血浆生物标志物可能与阿尔茨海默病 (AD) 相关的人口统计学、认知、遗传和神经影像学标志物存在差异。我们检查了来自 BioFINDER-2 ( n  = 400) 和 ADNI ( n  = 371)的 771 名认知正常、轻度认知障碍或痴呆的参与者。所有人都有 tau-PET ([ ¹⁸ F]RO948 in BioFINDER-2, [ ¹⁸F]flortaucipir in ADNI) 和 CSF p-tau181 生物标志物可用。血浆 p-tau181 和血浆/CSF p-tau217 仅在 BioFINDER-2 中可用。PET、CSF 和血浆 tau 生物标志物之间的一致性介于 66% 和 95% 之间。在整个组中，岭回归模型显示，增加的 CSF 和血浆 p-tau181 和 p-tau217 水平与高龄相关的 tau PET 和APOE无关ɛ4-携带和 Aβ-阳性，而颞叶皮层中 tau-PET 信号的增加与较差的认知能力和减少的皮层厚度相关。我们得出结论，tau 病理学的生物流体和神经影像标志物传达部分独立的信息，脑脊液和血浆 p-tau181 和 p-tau217 水平与 AD 的早期标志物（尤其是 Aβ-病理学）更紧密相关，而 tau-PET 显示最强与疾病进展的认知和神经退行性标志物的关联。